Nattokinase for Cardiovascular Health: Japan's Fermented Soy Enzyme Under Scrutiny

Nattokinase is a fibrinolytic enzyme isolated from natto, the fermented soybean dish that has been a Japanese breakfast staple for over a thousand years. Several small randomized trials show modest reductions in blood pressure and circulating fibrinogen. The mechanism is plausible, the safety record outside of bleeding-risk groups is good, and the supplement is widely sold — but no cardiovascular outcome trial has been completed, and the regulatory enthusiasm in Japan is not matched by U.S. or European guideline bodies.

Origin and mechanism

Nattokinase is produced by Bacillus subtilis var. natto during fermentation. Sumi and colleagues at Chicago University Medical School first isolated and characterized it in 1987, naming it for its parent food. It belongs to the subtilisin family of serine proteases and degrades fibrin directly, in addition to activating endogenous plasminogen. In vitro, nattokinase is roughly four times more potent than plasmin per unit weight at dissolving fibrin clots.

The enzyme is dosed in fibrinolytic units (FU), a measure of fibrin-degrading activity. Standard supplement doses are 2,000–4,000 FU per day, equivalent to roughly 100–200 mg of standardized extract.

Blood pressure trials

Three RCTs constitute the core blood pressure evidence. Kim et al. (2008) randomized 86 hypertensive Korean adults to 2,000 FU/day or placebo for 8 weeks; systolic BP fell 5.5 mm Hg more in the treatment group. Jensen et al. (2016) replicated the effect in 79 American adults, with a 4-mm Hg systolic reduction. A 2022 trial by Chen et al. in 92 Taiwanese adults with stage-1 hypertension found similar reductions, with effects more pronounced in men. The pooled effect across these studies is roughly 4–6 mm Hg systolic and 2–3 mm Hg diastolic — comparable to a low-dose ACE inhibitor.

The 2022 systematic review by Chen identified seven trials and concluded the evidence supported modest BP-lowering, with limitations around sample size and study duration. No trial exceeds 12 weeks.

Fibrinogen, clot dissolution, and stroke claims

Nattokinase reliably lowers plasma fibrinogen by 7–10 percent across multiple trials. Fibrinogen is a cardiovascular risk marker but lowering it pharmacologically has not been independently shown to reduce events. Hsia et al. (2009) reported reductions in factor VII and factor VIII activity in subjects taking 4,000 FU/day for two months. Pais et al. (2006) demonstrated dose-dependent reductions in d-dimer and prothrombin fragments.

Marketing claims about nattokinase "dissolving existing clots" overstate the case. The compound has shown clot-dissolving activity in vitro and in animal thrombosis models. The single human study suggesting reversal of carotid plaque (Ren et al., 2017) was unblinded, used non-standardized imaging, and has not been replicated. Clinicians treating acute thrombosis use enoxaparin, warfarin, DOACs, or thrombolytics — not natto extract.

Bleeding interactions are real

Case reports describe excessive bleeding when nattokinase is combined with warfarin, aspirin, clopidogrel, or DOACs. Two cerebral hemorrhages have been reported in patients on combination therapy. Surgery within two weeks of nattokinase use is generally contraindicated. The supplement should be stopped at least 7–14 days before any planned procedure.

Nattokinase preserves the menaquinone (vitamin K2 MK-7) content of natto only when whole-food natto is consumed. The isolated enzyme supplement does not contain meaningful K2, so users on warfarin do not need to manage INR for K2 — but they do still face the bleeding risk from the enzyme's direct fibrinolytic action.

Practical guidance

For mild hypertension that doesn't yet meet criteria for prescription therapy, nattokinase 2,000–4,000 FU/day is one of several reasonable adjuncts to lifestyle change — comparable in effect size to garlic extract, hibiscus tea, or magnesium repletion. It should not replace established therapy in moderate-to-severe hypertension. Anyone on anticoagulant or antiplatelet therapy should avoid it unless cleared by their cardiologist.

The most important caveat: marketing of nattokinase as a "blood thinner alternative" or as a means to reverse atherosclerotic plaque is not supported by adequately designed human outcome trials. The compound has earned a place as a possible adjunct for blood pressure with biologically plausible fibrinolytic effects, but it has not earned the cardiovascular outcome evidence that statins, ACE inhibitors, or anticoagulants have. Treat it as adjunctive, monitor for bruising, and consider stopping before any procedure.